Not too long ago the FDA unveiled a proposed rule that would revise the way in which DTC (direct-to-consumer) drug advertising would have to deal with contraindication and side effect information.  We thought our readers would like to know (if they didn’t already).  But because we’re lazy – and it’s late on a Friday afternoon – we’re content to refer you to the posts on the proposal that are already available at the Mass Torts and FDA Law blogs.